ReviewTherapeutic advances in medical oncology2023
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS).
Review in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- MRI insights into endometrial stromal tumors.Insights into imaging · 2026Article
- Comparative Analysis of Cyclin E1 Expression in Uterine Leiomyosarcomas and Leiomyomas.Diseases (Basel, Switzerland) · 2026Article
- Giant low-grade endometrial stromal sarcoma with extensive sex cord-like differentiation: a case report.International journal of surgery case reports · 2026Article
- Metastatic Uterine Sarcomas: A Retrospective Analysis on Clinical Outcomes and Biology.Cureus · 2026Article
- Full-term delivery in pregnancy complicated with suspected residual cervical alveolar soft part sarcoma: a case report and literature review.BMC pregnancy and childbirth · 2026Review
- Extended and Repeated Cytoreductive Surgery in Recurrent Uterine Leiomyosarcoma: A Narrative Review.Cancers · 2026Review
- Review
- Article
- When Local Beats Systemic: Durable Control of Metastatic Undifferentiated Uterine Sarcoma and Surveillance Uncovering a Second Primary.Acta medica Lituanica · 2026Article
- Uterine sarcoma: A 10-year retrospective analysis of clinicopathological and prognostic factors of surgically treated cases.Ecancermedicalscience · 2026Article
- MicroRNAs in Uterine Leiomyosarcoma: From Molecular Mechanisms to Clinical Applications.International journal of molecular sciences · 2025Review
- High visceral-to-subcutaneous fat area ratio is an unfavorable prognostic indicator in patients with uterine sarcoma.Japanese journal of radiology · 2025Article
- High-grade endometrial stromal sarcoma presenting with multiple brain metastases: a case report.Journal of medical case reports · 2025Article
- From Benign Polyp to High-Grade Endometrial Sarcoma: A Case Report with Imaging Correlation.Diagnostics (Basel, Switzerland) · 2025Article
- Survival guided adaptive clustering enhances mortality risk stratification and radiotherapy guidance in early stage uterine sarcoma.Scientific reports · 2025Article
- Endometrial Stromal Sarcoma: An Update.Cancers · 2025Review
- Uterine Spindle Cell Sarcoma Presenting With Lower Gastrointestinal Bleeding: A Case Report.Cureus · 2025Article
- Giant Uterine Tumor Compatible With Sarcoma.Cureus · 2025Article
- Molecular Insights in Endometrial Stromal Sarcomas: Exploring New Targets for Novel Therapeutic Approaches.Biomolecules · 2025Review
- The value of multiparametric MRI-based habitat imaging for differentiating uterine sarcomas from atypical leiomyomas: a multicentre study.Abdominal radiology (New York) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine sarcomas are very infrequent and heterogeneous entities. Due to its rarity, pathological diagnosis, surgical management, and systemic treatment are challenging. Treatment decision process in these tumors should be taken in a multidisciplinary tumor board. Available evidence is low and, in many cases, based on case series or clinical trials in which these tumors have been included with other soft tissue sarcoma. In these guidelines, we have tried to summarize the most relevant evidence in the diagnosis, staging, pathological disparities, surgical management, systemic treatment, and follow-up of uterine sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.